Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

- March 14th, 2019

Axovant Sciences (NASDAQ:AXGT) has announced the pricing of its underwritten public offering of 26.6 million of its common shares at a price of US$1.50 per share. As quoted in the press release: Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.  All … Continued

Axovant Sciences (NASDAQ:AXGT) has announced the pricing of its underwritten public offering of 26.6 million of its common shares at a price of US$1.50 per share.

As quoted in the press release:

Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,000,000 of its common shares on the same terms and conditions.  The offering is expected to close on March 18, 2019, subject to customary closing conditions.

Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager.

A shelf registration statement relating to the offered common shares was filed with the Securities and Exchange Commission (SEC), and was declared effective on January 13, 2017.  A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov.  Copies of the final prospectus supplement and accompanying base prospectus related to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com

Click here to read the full press release.

The newest developments in genetics investing

 
Find out what to watch for in the world of genetics

Leave a Reply

Your email address will not be published. Required fields are marked *